The picture of future therapy

Area of Science:

• Infectious Diseases
• Virology
• Pharmacology

Background:

• Highly active antiretroviral therapy (HAART), combining nucleoside reverse transcriptase inhibitors (NRTIs) with protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs), is the current standard for HIV treatment.
• Clinicians anticipate future challenges in HIV management, including concerns about clinical data quality, treatment costs, and virological failure.

Purpose of the Study:

• To address the identified causes of virological failure in HIV treatment.
• To explore and investigate novel combination regimens and antiviral drugs.
• To identify and research new therapeutic targets for antiviral drug development.

Main Methods:

• Review and analysis of existing studies on combination antiretroviral therapy.
• Investigation into various causes of virological failure, including compliance, toxicity, drug interactions, resistance, and insufficient potency.
• Exploration of emerging therapeutic strategies and drug targets in antiviral research.

Main Results:

• Several factors contributing to virological failure have been identified.
• Ongoing research is evaluating new drug combinations and individual agents.
• New targets for antiviral drug development are under active investigation.

Conclusions:

• Despite the effectiveness of HAART, challenges related to treatment efficacy and cost necessitate ongoing research.
• The development of new antiretroviral drugs and therapeutic strategies is crucial for overcoming treatment failures and improving patient outcomes in HIV management.
• Continued investigation into novel drug targets holds promise for future HIV therapies.